This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies

This study has been completed.
Information provided by (Responsible Party):
Takehiko Mori, M.D., Ph.D., Keio University Identifier:
First received: December 28, 2005
Last updated: April 5, 2012
Last verified: April 2012
The primary purpose of this study is to evaluate the safety and efficacy of cord blood transplantation for adult patients with hematologic malignancies including refractory acute leukemia. The transplant procedure was determined in detail according to the previously published report showing a high survival, so that the investigators could expect a similar result.

Condition Intervention Phase
Acute Myelogenous Leukemia Acute Lymphoblastic Leukemia Chronic Myelogenous Leukemia Myelodysplastic Syndrome Procedure: Cord blood transplantation Radiation: TBI Drug: cyclophosphamide Drug: cytarabine Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1/2 Study of Cord Blood Transplantation From Unrelated Donor for Adult Patients With Hematologic Malignancies Using Myeloablative Conditioning Regimen

Resource links provided by NLM:

Further study details as provided by Takehiko Mori, M.D., Ph.D., Keio University:

Primary Outcome Measures:
  • Non-relapse mortality at 1 year [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • Engraftment [ Time Frame: day 56 ]
  • Disease free survival [ Time Frame: 1 year ]
  • Overall survival [ Time Frame: 1 year ]
  • Incidence of acute and chronic graft-versus-host disease [ Time Frame: day100 and 1 year ]
  • Incidence of infectious complication [ Time Frame: 1year ]
  • Duration of hospitalization [ Time Frame: 1 year ]
  • Immune reconstitution after transplantation [ Time Frame: 1 year ]

Enrollment: 33
Study Start Date: January 2006
Study Completion Date: January 2011
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Procedure: Cord blood transplantation
    unrelated cord blood transplantation
    Radiation: TBI
    Total body irradiation (TBI) 12Gy
    Drug: cyclophosphamide
    cyclophosphamide 120mg/kg
    Drug: cytarabine
    cytarabine 3g/m2x4
Detailed Description:
Although cord blood is considered as an alternative donor source for allogeneic hematopoietic stem cell transplantation, its procedure has yet to be standardized. Recently, a single institute result of cord blood transplantation for adult patients with hematologic malignancies have been reported by Takahashi et al (Blood 2004:104;3813-3820), in which the survival was significantly better than that of bone marrow transplantation from unrelated donor. The purpose of this study was to reevaluate the safety and efficacy of cord blood transplantation for adult patients with hematologic malignancies using the same transplant procedures in a multi-institutional setting.

Ages Eligible for Study:   20 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical diagnosis of acute leukemia, chronic myelogenous leukemia, and myelodysplastic syndrome
  • Lack of HLA-identical or 1 locus mismatched related donor
  • Age over 20, and under 55
  • Performance status 0 or 1
  • No moderate or sever organ dysfunction (liver, kidney, heart, lungs)
  • No anti-HLA antibody
  • Informed consent was obtained

Exclusion Criteria:

  • Uncontrollable diabetes
  • Uncontrollable hypertension
  • Active infection
  • TPHA, HBs-Ag, HCV-Ab positive
  • HTLV-I, HIV positive
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00270881

Keio University School of Medicine
Tokyo, Japan, 160-8582
Sponsors and Collaborators
Keio University
Study Chair: Hisashi Sakamaki, M.D., Ph.D. Tokyo Metropolitan Komagome Hospital
  More Information

Responsible Party: Takehiko Mori, M.D., Ph.D., Dr., Keio University Identifier: NCT00270881     History of Changes
Other Study ID Numbers: KSGCT-CB2005
Study First Received: December 28, 2005
Last Updated: April 5, 2012

Keywords provided by Takehiko Mori, M.D., Ph.D., Keio University:
cord blood transplantation
myeloablative regimen
hematologic malignancies

Additional relevant MeSH terms:
Myelodysplastic Syndromes
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Myeloproliferative Disorders
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antimetabolites, Antineoplastic processed this record on September 21, 2017